NewAmsterdam Pharma Company N.V. (NAMS)

SEC filing

NewAmsterdam Pharma Company N.V.

NAMS · CIK 1936258

4 · Aug 25, 2026 · Director, Chief Scientific Officer Kastelein Johannes Jacob Pieter sold 125K shares at $26.91/share ($3.4M); exercised options for 250K shares

Director, Chief Scientific Officer Kastelein Johannes Jacob Pieter sold 125K shares at $26.91/share ($3.4M); exercised options for 250K shares

Filed: Aug 25, 2026
Period: Aug 24, 2026
Accession: 0001193125-26-365202
Filer: NewAmsterdam Pharma Co N.V.
Exhibits: EX-24

View on SEC.gov All SEC filings

Filing document

xslF345X06/ownership.xml

xslF345X06/ownership.xmlSEC.gov

Exhibits

EX-24

nams-ex24.htm

nams-ex24.htmSEC.gov

Other files

Graphics and non-inline formats (not embedded below).

4ownership.xml
Open SEC.gov